Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids

Abstract

BackgroundTumor-specific cytotoxic T cells and T cell receptors are effective tools for cancer immunotherapy. Most efforts to identify them rely on known antigens or lymphocytes that have infiltrated into the tumor bed. Approaches to empirically identify tumor-targeting T cells and T cell receptors by exploiting all antigens expressed on tumor cell surfaces are not well developed for most carcinomas, including pancreatic cancer.MethodsAutologous tumor organoids were stimulated with T cells from the patients’ peripheral blood for 2 weeks to generate the organoid-primed T (opT) cells. opT cell phenotype was analyzed by monitoring changes in the expression levels of 28 cell surface and checkpoint proteins. Expression of ligands of the immune checkpoints was investigated by immunohistochemistry staining. T cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) and assayed by flow cytometry to monitor tumor-induced T cell proliferation changes. opT cell-mediated killing of three-dimensional organoids was measured using an M30 ELISA kit. T cell receptors (TCRs) were identified by deep sequencing of gDNA isolated from T cells, and the TCR specificity was confirmed by transferring TCRs to the T cell line SKW-3 or donor T cells.ResultsThe co-culture was effective in the generation of CD8 + or CD4+opT cells. The opT cells killed autologous tumors in a granzyme B or Fas-Fas ligand-dependent manner and expressed markers of tissue-resident memory phenotype. Each patient-derived opT cell culture displayed a unique complement of checkpoint proteins. Interestingly, only NKG2A blockade showed a potent increase in the interferon-γ production compared with blocking programmed cell death protein 1 (PD-1) or programmed cell death ligand 1 (PD-L1) or TIM3 or TIGIT or LAG3. Importantly, TCR sequencing demonstrated a dramatic clonal expansion of T cells with a restricted subset of TCRs. Cloning and transferring the TCRs to heterologous T cells was sufficient to confer tumor cell recognition and cytotoxic properties in a patient-specific manner.ConclusionWe report a platform for expanding tumor-targeting T cells from the peripheral blood of patients with pancreatic cancer. We identify the NKG2A-HLA-E axis as a potentially important checkpoint for CD8 +T cells for pancreatic cancer. Lastly, we demonstrate empirical identification of tumor-targeting TCRs that can be used for TCR-therapeutics.

Exploring the pathogenesis linking traumatic brain injury and epilepsy via bioinformatic analyses

“…These genes are all involved in the immune response. Several studies on other diseases have revealed the associations of hub genes expression with interferon gamma release ( Johnson et al, 2020 ; Meng et al, 2021 ). Yet, in-depth mechanism studies on PTE about these hub genes and interferon gamma are needed.…”

Cancer organoid co-culture model system: Novel approach to guide precision medicine

“…This novel platform may guide clinical treatment at the microscopic level and benefit patients without needing long waiting periods based on advances in organoid culture techniques. Moreover, several studies have focused on generating tumor-specific lymphocytes for tumor-targeting therapy through co-culture ( 45 – 48 , 51 , 52 ). This method, with its excellent prospects, may achieve more accurate cell therapy with better clinical efficacy.…”

“…The era of checkpoint blockade immunotherapy is in full swing, exhibiting outstanding efficacy by unblocking negatively controlled T cells and triggering anticancer T cell responses. Coculturing PDO with immune cells combined with checkpoint blockade inhibitors has been applied in a series of studies on cancer precision medicine (51)(52)(53)56), providing important insights into predicting precision therapy efficacy with PDO. This process takes nearly ten days and includes cancer organoid establishment after surgical resection, preparation of immune cells, co-culture, drug testing, and determination of efficacy.…”

Clinical applications of 3D normal and breast cancer organoids: A review of concepts and methods

“…72 This approach has been used to induce and characterize tumor-specific T-cell responses and their specific T-cell receptors. 73,74 Because of the paramount importance of the interaction of BC epithelial cells with surrounding stromal and immune cells within the tissue microenvironment, methods have emerged for the study of this interaction using organoid co-culture. Since the stromal and immune compartments can play both pro and antitumor roles during BC development and progression, co-culture systems are an attractive model to parse out these diverse roles and interactions during pathogenesis.…”

“…72 This approach has been used to induce and characterize tumor-specific T-cell responses and their specific T-cell receptors. 73,74…”